Reardon Andrew sold LGND
March 4, 2026 · Form 4 insider transaction
Reardon Andrew sold 300 shares of Ligand Pharmaceuticals Incorporated at $201.70 per share, a transaction worth $60.5K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Disposed (sell-side)
Shares
300
Price
$201.70
Total value
$60.5K
InsiderReardon Andrew
Role—
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateMarch 4, 2026
Filing dateMarch 6, 2026
Shares owned after41,069
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1.